| Literature DB >> 29615750 |
Marlies Antlanger1, Stefan Aschauer2, Andreas A Kammerlander2, Franz Duca2, Marcus D Säemann3,4, Diana Bonderman2, Julia Mascherbauer5.
Abstract
Diffuse myocardial fibrosis is a key pathophysiologic feature in heart failure and can be quantified by cardiac magnetic resonance (CMR) T1 mapping. However, increases in myocardial free water also prolong native T1 times and may impact fibrosis quantification. Thus far, the impact of systemic patient volume status remains unclear. In this study, native T1 time by CMR was investigated in hemodialysis (HD) patients (n = 37) and compared with healthy controls (n = 35). Volume status was quantified by bioimpedance spectroscopy and correlated with CMR T1 time. While no differences between HD patients and controls were present with regard to age (p = 0.180), height (p = 0.535), weight (p = 0.559) and left ventricular (LV) ejection fraction (p = 0.273), cardiac size was significantly larger in HD patients (LV end-diastolic volume 164 ± 53 vs. 132 ± 26 ml, p = 0.002). Fluid overloaded HD patients had significantly longer native T1 times than normovolemic HD patients and healthy controls (1,042 ± 46 vs. 1,005 ± 49 vs. 998 ± 47 ms, p = 0.030). By regression analysis, T1 time was significantly associated with fluid status (r = 0.530, p = 0.009, post-HD fluid status). Our data strongly indicate that native CMR T1 time is significantly influenced by systemic volume status. As fluid overload is common in patients with cardiovascular diseases, this finding is important and requires further study.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29615750 PMCID: PMC5882796 DOI: 10.1038/s41598-018-23868-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Native T1 map of a HD patient. Midventricular short-axis slice, myocardial region of interest was traced manually (circled area). Modified Look-Locker inversion recovery sequence with a 5(3)3 prototype was used to calculate T1 time.
Baseline characteristics.
| Variable | HD patients (n = 37) |
|---|---|
|
| |
| HD vintage, years | 3.0 ± 4.6 |
| Prior KTX, % | 43 |
| Residual urine >500 ml/d, % | 48 |
| AVF, % | 78 |
| Ultrafiltration, L | 2.3 ± 1.3 |
| HD duration, h | 4.0 ± 0.3 |
| Blood flow, ml/min | 293 ± 45 |
| RRsys, mmHg | 146 ± 23 |
| RRdiast, mmHg | 80 ± 15 |
|
| |
| Underlying renal disease, % | |
| Vascular | 8 |
| Glomerular | 31 |
| Polycystic | 8 |
| Tubulointerstitial | 8 |
| Diabetic | 11 |
| Other/unknown | 33 |
| Arterial hypertension, % | 87 |
| Coronary artery disease, % | 27 |
| Atrial fibrillation, % | 8 |
| Diabetes mellitus, % | 14 |
| COPD, % | 14 |
| Peripheral artery disease, % | 14 |
| Cerebrovascular disease, % | 8 |
|
| |
| Hemoglobin, g/dL | 10.4 ± 1.0 |
| Ferritin, μg/l | 318 ± 335 |
| Transferrin saturation, % | 20 ± 12 |
| PTH, pg/mL | 459 ± 474 |
| 25-OH vitamin D, nmol/L | 45 ± 30 |
| 1,25-OH vitamin D, pg/mL | 20 ± 13 |
| HbA1c, % | 5.3 ± 1.1 |
| Triglycerides, mg/dL | 157 ± 98 |
| Total cholesterol, mg/dL | 166 ± 40 |
| Low-density cholesterol, mg/dL | 94 ± 32 |
| High-density cholesterol, mg/dL | 43 ± 19 |
| NT pro-BNP, pg/mL | 3,889 [2,012-12,468] |
|
| |
| Left ventricular diameter, mm | 48 ± 7 |
| Right ventricular diameter, mm | 32 ± 6 |
| Left atrial diameter, mm | 56 ± 8 |
| Right atrial diameter, mm | 54 ± 7 |
| Interventricular septum, mm | 14.7 ± 2.8 |
| sPAP, mmHg | 46 ± 12 |
| Peak E ms/s | 0.9 ± 0.4 |
| Peak A ms/s | 0.8 ± 0.2 |
| E/A ratio | 0.56 ± 0.63 |
| E’ medial m/s | 0.07 ± 0.02 |
| E/E’ ratio | 13.5 ± 7.6 |
|
| |
| None, % | 6 |
| Grade 1, % | 61 |
| Grade 2, % | 24 |
| Grade 4, % | 9 |
|
| |
| Fluid overload pre-HD, L | 2.6 ± 2.3 |
| Fluid overload pre-HD, %ECV | 13.9 ± 12.0 |
| Fluid overload post-HD, L | 0.4 ± 2.7 |
| Fluid overload post-HD, %ECV | 1.8 ± 15.7 |
| Total body water, L | 38.2 ± 7.3 |
| Extracellular volume, L | 18.2 ± 3.1 |
| Intracellular volume, L | 19.8 ± 4.6 |
| Lean tissue mass, kg | 42.7 ± 12.6 |
| Adipose tissue mass, kg | 25.6 ± 12.0 |
| Lean tissue index | 14.6 ± 3.4 |
| Fat tissue index | 9.2 ± 4.6 |
| Body cell mass, kg | 24.2 ± 8.5 |
HD, hemodialysis; KTX, kidney transplantation; AVF, arteriovenous fistula; RR, blood pressure; COPD, chronic obstructive pulmonary disease; PTH, parathyroid hormone; NT pro-BNP, N-terminal prohormone of brain natriuretic peptide; sPAP; systolic pulmonary artery pressure; E, early medial diastolic mitral velocity; A, late medial mitral velocity; E’, early lateral diastolic mitral velocity; ECV, extracellular volume.
Cardiac magnetic resonance imaging variables.
| Variable | Healthy controls (n = 35) | HD patients (n = 37) | p-value |
|---|---|---|---|
| Age, years | 43 ± 17 | 49 ± 16 | 0.180 |
| Height, cm | 170 ± 10 | 169 ± 9 | 0.535 |
| Weight, kg | 71 ± 12 | 70 ± 11 | 0.559 |
| BMI, kg/m2 | 24.5 ± 3.6 | 24.4 ± 3.4 | 0.873 |
| IVS, mm | 9 [8–10] | 14 [11–16] |
|
| LV-EDD, mm | 47 ± 5 | 51 ± 8 |
|
| RV-EDD, mm | 37 ± 6 | 37 ± 6 | 0.961 |
| LA, mm | 54 ± 6 | 60 ± 9 |
|
| LA area, cm2 | 21 ± 5 | 27 ± 8 |
|
| RA, mm | 55 ± 6 | 57 ± 9 | 0.233 |
| RA area, cm2 | 21 [18–24] | 23 [21–26] | 0.731 |
| Ascending aorta, mm | 32 ± 4 | 35 ± 4 |
|
| Pulmonary trunk, mm | 22 ± 3 | 29 ± 4 |
|
| LV-EF, % | 65 ± 7 | 63 ± 9 | 0.273 |
| LV-EDV, mL | 132 ± 26 | 164 ± 53 |
|
| LV-ESV, mL | 45 [37–54] | 53 [44–74] |
|
| LV-SV, mL | 85 ± 19 | 102 ± 32 |
|
| RV-EF, % | 60 ± 8 | 59 ± 7 | 0.581 |
| RV-EDV, mL | 139 ± 27 | 160 ± 45 |
|
| RV-ESV, mL | 57 ± 16 | 66 ± 22 |
|
| RV-SV, mL | 82 ± 19 | 95 ± 28 |
|
| Cardiac output, L/min | 5.9 ± 1.7 | 7.3 ± 2.2 |
|
| LV mass, g | 108 ± 21 | 172 ± 53 |
|
| Native T1 time (SA), ms | 998 ± 47 | 1,022 ± 50 |
|
HD, hemodialysis; BMI, body mass index; IVS, interventricular septum; LV, left ventricle, RV, right ventricle, RA, right atrium; EDD, enddiastolic diameter; LA, left atrium; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; SA, short axis.
Clinical and CMR values of fluid overloaded versus normovolemic HD patients.
| Variable | Normohydrated (n = 17) | Fluid overloaded (n = 13) | p-value |
|---|---|---|---|
| Fluid overload pre-HD, %ECV | 5.8 ± 8.5 | 24.5 ± 6.1 |
|
| Fluid overload post-HD, %ECV | −9.4 ± 12.3 | 13.9 ± 8.2 |
|
| Age, years | 48 ± 19 | 53 ± 14 | 0.441 |
| BMI, kg/m2 | 26.3 ± 3.4 | 22.8 ± 2.0 |
|
| HD vintage, years | 2.1 ± 1.9 | 5.0 ± 7.0 | 0.110 |
| RRsys, mmHg | 146 ± 24 | 148 ± 25 | 0.856 |
| RRdiast, mmHg | 80 ± 16 | 80 ± 16 | 0.995 |
| Hemoglobin, g/dL | 10.5 ± 0.9 | 10.4 ± 1.1 | 0.819 |
| NT pro-BNP, pg/mL | 2,525 [1,493–3,908] | 11,694 [5,350–20,424] |
|
| Coronary artery disease, % | 18 | 54 |
|
| Atrial fibrillation, % | 6 | 15 | 0.397 |
| Diabetes mellitus, % | 6 | 23 | 0.204 |
| IVS, mm | 13 ± 3 | 14 ± 3 | 0.526 |
| LA, mm | 59 ± 7 | 61 ± 13 | 0.532 |
| LV-EF, % | 66 ± 6 | 62 ± 10 | 0.247 |
| LV-EDV, mL | 140 ± 41 | 186 ± 62 |
|
| RA, mm | 56 ± 6 | 60 ± 11 | 0.214 |
| RV-EF, % | 59 ± 8 | 59 ± 6 | 0.913 |
| RV-EDV, mL | 148 ± 36 | 173 ± 58 | 0.162 |
| LV cardiac output, L/min | 6.7 ± 1.6 | 7.9 ± 3.0 | 0.193 |
| RV cardiac output, L/min | 6.4 ± 1.3 | 7.0 ± 2.7 | 0.445 |
| LV mass, g | 147 ± 39 | 194 ± 64 |
|
HD, hemodialysis, ECV, extracellular volume; BMI, body mass index; RR, blood pressure; NT pro-BNP, N-terminal prohormone of brain natriuretic peptide; IVS, interventricular septum; LA, left atrium; LV, left ventricular; EF, ejection fraction; LV-EDV, left ventricular end-diastolic volume; RA, right atrium; RV, right ventricle.
Figure 2Correlation plots of fluid status and myocardial T1 time (short axis). (A) Absolute pre-HD fluid status in Liters above/below ideal extracellular volume. (B) Relative pre-HD fluid status in % above/below ideal extracellular volume. Blue circles represent normovolemic patients; green circles represent fluid overloaded patients.
Figure 3Correlation plot of left ventricular mass and myocardial T1 time (HD patients only).